Skip to main content
. Author manuscript; available in PMC: 2016 Jul 7.
Published in final edited form as: Nutr Cancer. 2016 Jan 15;68(1):154–164. doi: 10.1080/01635581.2016.1115104

Figure 5.

Figure 5

Expression of miR-155 targets in response to genistein in breast cancer cells expressing control or miR-155 vector. MDA-MB-435 or Hs578t cells expressing control or miR-155 vector were treated with vehicle or genistein (1 or 5μM) for 48 h. Lysates were western blotted for miR-155 targets. A: Representative western blots are shown for MDA-MB-435 (left) or Hs578t (right) cell lysates. B–F: The fold changes in protein expression from N = 3 ± SEM are indicated for (B) FOXO3a, (C) p27, (D) casein kinase 1α, (E) PTEN, or (F) β-catenin. *P < 0.05, genistein treatments compared to vehicle; #P < 0.05, cells ectopically expressing miR-155 compared with cells expressing control vector.